Lista de obras - Mikko Neuvonen - Dominio Público Uruguay

A population-based, complete follow-up of 146 consecutive patients after transanal mucosectomy for Hirschsprung disease

artículo científico publicado en 2015

Amiodarone Interacts with Simvastatin but not with Pravastatin Disposition Kinetics

Analgesic Plasma Concentrations of Oxycodone After Surgery for Breast Cancer-Which Factors Matter?

artículo científico publicado en 2017

Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response

artículo científico publicado en 2012

Benzodiazepine findings in blood and urine by gas chromatography and immunoassay

artículo científico publicado en 2000

CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe

artículo científico publicado en 2009

CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single-dose primaquine

artículo científico publicado en 2014

Carboxylesterase 1 Polymorphism Impairs Oseltamivir Bioactivation in Humans

Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans

artículo científico publicado en 2015

Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions .

artículo científico publicado en 2017

Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone

artículo científico publicado en 2016

Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans

artículo científico publicado en 2019

Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide

artículo científico publicado en 2005

Critical Differences between Enzyme Sources in Sensitivity to Detect Time-Dependent Inactivation of CYP2C8

artículo científico publicado en 2019

Cyclosporine markedly raises the plasma concentrations of repaglinide

artículo científico publicado en 2005

Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide

artículo científico publicado en 2008

Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans.

artículo científico publicado en 2009

Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide

artículo científico publicado en 2003

Effect of grapefruit juice on the bioactivation of prasugrel

artículo científico publicado en 2015

Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects

artículo científico publicado en 2003

Effect of rifampicin on the pharmacokinetics of pioglitazone

artículo científico publicado en 2006

Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl

artículo científico publicado en 2007

Effects of Genetic Variants on Carboxylesterase 1 Gene Expression, and Clopidogrel Pharmacokinetics and Antiplatelet Effects

artículo científico publicado en 2017

Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone

artículo científico publicado en 2010

Enzymatic oxidation of cholesterol: properties and functional effects of cholestenone in cell membranes

artículo científico publicado en 2014

Gemfibrozil considerably increases the plasma concentrations of rosiglitazone

artículo científico publicado en 2003

Gemfibrozil greatly increases plasma concentrations of cerivastatin

artículo científico publicado en 2002

Genome‐Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP

artículo científico publicado en 2024

Grapefruit juice enhances the exposure to oral oxycodone

artículo científico publicado en 2010

Grapefruit juice inhibits the metabolic activation of clopidogrel

artículo científico publicado en 2013

Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects

artículo científico publicado en 2013

High performance liquid chromatography-tandem mass spectrometry for the determination of bile acid concentrations in human plasma

artículo científico publicado en 2010

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

artículo científico publicado en 2004

Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation-A Potentially Beneficial Drug-Drug Interaction

scientific article published on 29 November 2019

Itraconazole, a potent inhibitor of P-glycoprotein, moderately increases plasma concentrations of oral morphine

artículo científico publicado en 2008

Ketamine coadministration attenuates morphine tolerance and leads to increased brain concentrations of both drugs in the rat.

artículo científico publicado en 2015

Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone

No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin

artículo científico publicado en 2009

No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone

artículo científico publicado en 2007

Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir

artículo científico publicado en 2010

Paroxetine Markedly Increases Plasma Concentrations of Ophthalmic Timolol; CYP2D6 Inhibitors May Increase the Risk of Cardiovascular Adverse Effects of 0.5% Timolol Eye Drops

article published in 2014

Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia

artículo científico publicado en 2003

Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes

artículo científico publicado en 2006

Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole

artículo científico publicado en 2002

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics

artículo científico publicado en 2005

Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide

artículo científico publicado en 2003

Rifampicin markedly decreases the exposure to oral and intravenous tramadol

artículo científico publicado en 2012

Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone

artículo científico publicado en 2009

Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites

artículo científico publicado en 2005

Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects

artículo científico publicado en 2006

SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

St John's wort greatly reduces the concentrations of oral oxycodone

artículo científico publicado en 2010

The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects

artículo científico publicado en 2004

The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range

artículo científico publicado en 2008

The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo

artículo científico publicado en 2008

The mineralocorticoid receptor antagonist spironolactone enhances morphine antinociception

artículo científico publicado en 2013

Ticagrelor Increases Exposure to the Breast Cancer Resistance Protein Substrate Rosuvastatin

artículo científico publicado en 2023

Voriconazole drastically increases exposure to oral oxycodone

artículo científico publicado en 2008

Lista de obras de Mikko Neuvonen

A population-based, complete follow-up of 146 consecutive patients after transanal mucosectomy for Hirschsprung disease

Amiodarone Interacts with Simvastatin but not with Pravastatin Disposition Kinetics

Analgesic Plasma Concentrations of Oxycodone After Surgery for Breast Cancer-Which Factors Matter?

Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response

Benzodiazepine findings in blood and urine by gas chromatography and immunoassay

CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe

CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single-dose primaquine

Carboxylesterase 1 Polymorphism Impairs Oseltamivir Bioactivation in Humans

Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans

Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions .

Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone

Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans

Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide

Critical Differences between Enzyme Sources in Sensitivity to Detect Time-Dependent Inactivation of CYP2C8

Cyclosporine markedly raises the plasma concentrations of repaglinide

Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide

Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans.

Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide

Effect of grapefruit juice on the bioactivation of prasugrel

Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects

Effect of rifampicin on the pharmacokinetics of pioglitazone

Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl

Effects of Genetic Variants on Carboxylesterase 1 Gene Expression, and Clopidogrel Pharmacokinetics and Antiplatelet Effects

Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone

Enzymatic oxidation of cholesterol: properties and functional effects of cholestenone in cell membranes

Gemfibrozil considerably increases the plasma concentrations of rosiglitazone

Gemfibrozil greatly increases plasma concentrations of cerivastatin

Genome‐Wide Association Study of Atorvastatin Pharmacokinetics: Associations With <i>SLCO1B1</i>, <i>UGT1A3</i>, and <i>LPP</i>

Grapefruit juice enhances the exposure to oral oxycodone

Grapefruit juice inhibits the metabolic activation of clopidogrel

Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects

High performance liquid chromatography-tandem mass spectrometry for the determination of bile acid concentrations in human plasma

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation-A Potentially Beneficial Drug-Drug Interaction

Itraconazole, a potent inhibitor of P-glycoprotein, moderately increases plasma concentrations of oral morphine

Ketamine coadministration attenuates morphine tolerance and leads to increased brain concentrations of both drugs in the rat.

Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone

No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin

No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone

Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir

Paroxetine Markedly Increases Plasma Concentrations of Ophthalmic Timolol; CYP2D6 Inhibitors May Increase the Risk of Cardiovascular Adverse Effects of 0.5% Timolol Eye Drops

Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia

Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes

Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics

Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide

Rifampicin markedly decreases the exposure to oral and intravenous tramadol

Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone

Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites

Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects

SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

St John's wort greatly reduces the concentrations of oral oxycodone

The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects

The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range

The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo

The mineralocorticoid receptor antagonist spironolactone enhances morphine antinociception

Ticagrelor Increases Exposure to the Breast Cancer Resistance Protein Substrate Rosuvastatin

Voriconazole drastically increases exposure to oral oxycodone